<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Actuate Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock</link>
<description>Latest news and press releases for Actuate Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 06 May 2026 12:45:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/actuate-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835425678dffbe2df0e13c4.webp</url>
<title>Actuate Therapeutics, Inc.</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock</link>
</image>
<item>
<title>Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-announces-key-appointment-of-industry-veteran-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-announces-key-appointment-of-industry-veteran-to-board-of-directors</guid>
<pubDate>Wed, 06 May 2026 12:45:00 GMT</pubDate>
<description>Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapiesCHICAGO and FORT WORTH, Texas, May 06, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced the appointment of Martin Huber, MD, as an Independent Director, effective immedi</description>
</item>
<item>
<title>Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-announces-nature-medicine-publication-of-clinical-trial-results-showing-doubling-of-the-rate-of-survival-with-elraglusib-plus-chemotherapy-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-announces-nature-medicine-publication-of-clinical-trial-results-showing-doubling-of-the-rate-of-survival-with-elraglusib-plus-chemotherapy-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib arm versus 22%</description>
</item>
<item>
<title>Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-launches-strategic-research-initiative-to-combine-elraglusib-with-ras-inhibitors</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-launches-strategic-research-initiative-to-combine-elraglusib-with-ras-inhibitors</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancersMechanisms of action</description>
</item>
<item>
<title>Actuate Therapeutics to Present at The Citizens Life Sciences Conference</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-to-present-at-the-citizens-life-sciences-conference-29</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-to-present-at-the-citizens-life-sciences-conference-29</guid>
<pubDate>Wed, 04 Mar 2026 22:00:00 GMT</pubDate>
<description>CHICAGO and FORT WORTH, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Dan Schmitt, President & CEO of the Company, will present at the Citizens Life Sciences Conference in Miami Beach, FL on Tuesday, March 1</description>
</item>
<item>
<title>Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Tue, 24 Feb 2026 13:45:00 GMT</pubDate>
<description>CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Dan Schmitt, President & CEO of the Company, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 2</description>
</item>
<item>
<title>Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-announces-plans-expand-134500011</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-announces-plans-expand-134500011</guid>
<pubDate>Wed, 21 Jan 2026 13:45:00 GMT</pubDate>
<description>-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate development of the elraglusib tablet in specific indications, including refractory melanoma and additional target solid tumor and hematologic cancers -Program builds on early clinical evidence of monotherapy activity observed in immune checkpoint inhibitor (CPI)-refractory metastatic melanoma in a previously completed trial CHICAGO and FORT WORTH, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ac</description>
</item>
<item>
<title>Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-reports-positive-data-134500878</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-reports-positive-data-134500878</guid>
<pubDate>Mon, 12 Jan 2026 13:45:00 GMT</pubDate>
<description>Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy aloneElraglusib combination reduced the risk of death by 38% compared with gemcitabine/nab-paclitaxel alone, with increased durable survival observed beyond 24 months CHICAGO and FORT WORTH, Texas, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage bioph</description>
</item>
<item>
<title>Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO...</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-reports-positive-follow-up-data-from-its-randomized-controlled-phase-2-trial-demonstrating-extended-long-term-overall-survival-benefit-with-elraglusib-plus-chemotherapy-for-metastatic-pancreatic-cancer-in-oral-presentation-at-asco</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-reports-positive-follow-up-data-from-its-randomized-controlled-phase-2-trial-demonstrating-extended-long-term-overall-survival-benefit-with-elraglusib-plus-chemotherapy-for-metastatic-pancreatic-cancer-in-oral-presentation-at-asco</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit</description>
</item>
<item>
<title>Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-announces-positive-patient-134500266</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-announces-positive-patient-134500266</guid>
<pubDate>Tue, 06 Jan 2026 13:45:00 GMT</pubDate>
<description>Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) observed in a patient with relapsed/refractory metastatic neuroblastomaClinical responses and disease control observed in 15 of 40 patients with difficult-to-treat refractory pediatric cancers, including 10 of 19 patients treated with elraglusib plus cyclophosphamide/topotecanData support advancing clinical development of elraglusib in Ewing sarcoma and po</description>
</item>
<item>
<title>Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-phase-2-metastatic-134500563</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-phase-2-metastatic-134500563</guid>
<pubDate>Thu, 18 Dec 2025 13:45:00 GMT</pubDate>
<description>CHICAGO and FORT WORTH, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3β (GSK-3β), today announced that data from its Phase 2 study evaluating elraglusib in metastatic pancreatic cancer have been selected for an oral presentation at the 2026 Amer</description>
</item>
<item>
<title>Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-announces-publication-positive-134500470</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-announces-publication-positive-134500470</guid>
<pubDate>Mon, 15 Dec 2025 13:45:00 GMT</pubDate>
<description>Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest that nuclear GSK-3β expression may help identify patients most likely to respond to treatment of a historically difficult-to-treat refractory disease CHICAGO and FORT WORTH, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of</description>
</item>
<item>
<title>Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-provides-fda-updated-124500804</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-provides-fda-updated-124500804</guid>
<pubDate>Mon, 22 Sep 2025 12:45:00 GMT</pubDate>
<description>Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides extended runway through key anticipated regulatory inflection pointsAdditional nonclinical studies are ongoing combining elraglusib with RAS inhibitors based on potential synergies and complimentary mechanisms of action CHICAGO and FORT WORTH, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeuti</description>
</item>
<item>
<title>Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-announces-closing-17-200100688</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-announces-closing-17-200100688</guid>
<pubDate>Thu, 11 Sep 2025 20:01:00 GMT</pubDate>
<description>CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the closing of its $17.25 million underwritten public offering of 2,464,286 shares of its common stock, including 321,428 additional shares of</description>
</item>
<item>
<title>Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-announces-pricing-15-123100525</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-announces-pricing-15-123100525</guid>
<pubDate>Wed, 10 Sep 2025 12:31:00 GMT</pubDate>
<description>CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it has priced an underwritten public offering of 2,142,858 shares of its common stock at an offering price of $7.00 per share of common s</description>
</item>
<item>
<title>Actuate Therapeutics Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-announces-proposed-public-200700058</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-announces-proposed-public-200700058</guid>
<pubDate>Tue, 09 Sep 2025 20:07:00 GMT</pubDate>
<description>CHICAGO and FORT WORTH, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company also expects to grant the underwr</description>
</item>
<item>
<title>Actuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-advances-era-oncology-140000704</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-advances-era-oncology-140000704</guid>
<pubDate>Mon, 25 Aug 2025 14:00:00 GMT</pubDate>
<description>Phase 2 study showed a doubling of the survival rate of metastatic pancreatic cancer patients at Year 1, an unprecedented outcome Technology is seen as transformative in increasing the effectiveness of treatment for a wide range of cancers CHICAGO, ...</description>
</item>
<item>
<title>Actuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy </title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-advances-a-new-era-in-oncology-with-potential-universal-backbone-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-advances-a-new-era-in-oncology-with-potential-universal-backbone-therapy</guid>
<pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
<description>Phase 2 study showed a doubling of the survival rate of metastatic pancreatic cancer patients at Year 1, an unprecedented outcomeTechnology is seen as</description>
</item>
<item>
<title>Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-collaborate-incyte-corporation-124500889</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-collaborate-incyte-corporation-124500889</guid>
<pubDate>Wed, 06 Aug 2025 12:45:00 GMT</pubDate>
<description>Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline Therapy CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the initiation of the Phase 1b t</description>
</item>
<item>
<title>Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-advances-clinical-program-124500534</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-advances-clinical-program-124500534</guid>
<pubDate>Thu, 17 Jul 2025 12:45:00 GMT</pubDate>
<description>- Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients - Prolonged and Durable Complete Responses (CRs) Observed in Two of Ten Refractory Ewing Sarcoma Patients - Two Additional Patients Had Durable Stable Disease in Notoriously Difficult-to-Treat Cancer - Confirmed Partial Response (PR) in a patient with a desmoplastic small-round-cell tumor (DSRCT) - Company Initiating Planning of Phase 2 Trial of Elraglusib in Children, Adolescents, and Adults with Refractory/Resistant Ew</description>
</item>
<item>
<title>Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial</title>
<link>https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-highlights-significant-sustained-131500192</link>
<guid isPermaLink="true">https://6ix.com/company/actuate-therapeutics-inc-common-stock/news/actuate-therapeutics-highlights-significant-sustained-131500192</guid>
<pubDate>Tue, 24 Jun 2025 13:15:00 GMT</pubDate>
<description>- Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) vs GnP alone - Patients with liver metastases experienced a 2.5x improvement in 1-year OS with a 38% reduction in risk of death when treated with elraglusib plus GnP CHICAGO and FORT WORTH, Texas, June 24, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc</description>
</item>
</channel>
</rss>